One Capital Management LLC Purchases 3,694 Shares of Danaher Co. (NYSE:DHR)

One Capital Management LLC lifted its position in Danaher Co. (NYSE:DHR) by 277.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,026 shares of the conglomerate’s stock after acquiring an additional 3,694 shares during the quarter. One Capital Management LLC’s holdings in Danaher were worth $1,256,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in DHR. Vanguard Group Inc. raised its holdings in shares of Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after acquiring an additional 4,163,657 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Danaher by 12.0% in the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after acquiring an additional 2,998,161 shares in the last quarter. Swedbank AB bought a new stake in shares of Danaher in the first quarter valued at about $676,545,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Danaher by 214.4% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock worth $711,051,000 after purchasing an additional 2,096,038 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DHR has been the subject of a number of recent research reports. Wells Fargo & Company initiated coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Bank of America boosted their price target on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Robert W. Baird boosted their price target on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Evercore ISI dropped their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Trading Up 0.7 %

Danaher stock opened at $276.06 on Tuesday. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The firm has a market cap of $199.37 billion, a PE ratio of 46.79, a P/E/G ratio of 4.48 and a beta of 0.83. The stock’s 50 day simple moving average is $265.25 and its two-hundred day simple moving average is $256.67. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the company earned $2.05 EPS. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. Analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.